Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019

Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria

“…The widespread of CR-GNB isolates have constituted a major public health problem ( Zhang et al, 2018 ). Although there are a few novel agents such as ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam, they are not universally active against all CR-GNB and are cost-prohibitive or are not readily available in certain settings ( Wong and van Duin, 2017 , Yu et al, 2021 , Jean et al, 2022 ). More importantly, KPC-producing K. pneumoniae isolates resistant to ceftazidime/avibactam have been reported recently, including isolates with emergence of resistance following exposure to this agent ( Shi et al, 2020 ).…”

“…While carbapenem resistance was at relatively low prevalence among P. aeruginosa and A. baumannii , the prevalence among the Enterobacterales was growing, leading to the concern for a potential rise of untreatable community-acquired infections ( Tangden and Giske, 2015 ). Imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, approved to treat CR-GNB infections currently, are capable of hydrolysing Ambler class A and C enzymes but are not effective against class B/D β-lactamases ( Wong and van Duin, 2017 , Yu et al, 2021 , Jean et al, 2022 ). Ceftolozane/tazobactam have been approved for the treatment of infections caused by MDR.…”

Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review

“…Recently, the antibacterial drug Fetroja (Shionogi & Co.) got approval from FDA for the treatment of gram-negative bacteria-mediated cUTI in patients having limited treatment options due to hypersensitive history. The list of antibiotics currently in the phase of clinical development against various critical superbugs is summarized in Table 5 [67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85].…”

Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae

“…cUTIs occur in patients having a structural or functional abnormality in their genitourinary tract or through infection of urinary catheters ( Melekos and Naber, 2000 ; Kongnakorn et al., 2019 ). Most of the challenging cUTIs are caused by Gram-negative bacteria, such as Escherichia coli and Klebsiella pneumoniae , that can resist multiple antimicrobial agents by producing extended-spectrum β-lactamase (ESBL) enzymes, such as CTX-M enzymes, AmpC β-lactamases, and carbapenemases ( Chatterjee et al., 2021 ; Syed, 2021 ; Jean et al., 2022 ; López Montesinos et al., 2022 ; Wald-Dickler et al., 2022 ; Zilberberg et al., 2022 ). By prolonging hospitalization, cUTIs have imposed a serious burden on healthcare systems ( Food and Drug Administration, 2018 ; Vallejo-Torres et al., 2018 ; Zilberberg et al., 2021 ).…”